Browse the evidence

Weight loss achieved via a very-low-carbohydrate, high-saturated-fat diet does not impair endothelial function (measured by flow-mediated dilatation) and improves other cardiovascular risk markers, refuting the hypothesis that such diets inherently damage vascular health.

If you are overweight and have abdominal obesity, losing weight through a very-low-carbohydrate, high-saturated-fat diet does not appear to harm your blood vessel health (endothelial function) over an 8-week period. In fact, other markers of inflammation and clotting risk improved. The key factor seems to be the weight loss itself, which may counteract the negative effects of high saturated fat intake seen in people who don't lose weight.

A very-low-carbohydrate, high-saturated-fat diet leads to greater weight loss and abdominal fat reduction compared to a high-carbohydrate, low-saturated-fat diet, but results in less favorable changes in LDL cholesterol and C-reactive protein.

A very-low-carbohydrate diet may help you lose slightly more weight and abdominal fat than a high-carbohydrate diet over 8 weeks. However, this comes at the cost of less improvement in LDL cholesterol and inflammation (CRP) compared to a high-carbohydrate diet. If you have high cholesterol or inflammation, a high-carbohydrate diet might be a better choice for your cardiovascular markers, even if weight loss is slightly slower.

Subgingival instrumentation (periodontal therapy) significantly reduces glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes, demonstrating a bidirectional benefit where treating periodontitis improves metabolic control.

If you have diabetes and gum disease, getting your gums treated by a dentist is not just about saving your teeth; it helps lower your blood sugar levels. Standard cleaning (subgingival instrumentation) has been shown to reduce HbA1c by nearly 0.3%, which is clinically meaningful for metabolic control.

Obesity increases the risk and severity of periodontitis through systemic inflammation and adipokine release, creating a bidirectional relationship where higher BMI correlates with poorer periodontal outcomes.

Higher body weight is biologically linked to more severe gum disease due to inflammation. If you are overweight, you are at higher risk for gum bone loss. Managing weight and treating gum disease are interconnected parts of your overall health.

Tenofovir alafenamide (TAF) is associated with greater weight gain compared to Tenofovir disoproxil fumarate (TDF), which appears to have a weight-mitigating effect.

If your HIV medication contains TAF (tenofovir alafenamide), you may gain more weight than if you were on TDF (tenofovir disoproxil fumarate). TDF seems to help mitigate weight gain. If you are concerned about weight, ask your doctor if switching your tenofovir prodrug from TAF to TDF is an option for you, keeping in mind that TDF may have other side effects like kidney or bone issues.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) reduce systemic and tissue inflammation through mechanisms that are partially independent of weight loss and metabolic improvements.

GLP-1 medications like semaglutide and liraglutide offer health benefits beyond just weight loss. They directly reduce inflammation in your body, which helps protect your heart, kidneys, and joints. This happens through direct actions on your immune system and nerves, not just by making you thinner. Even if your weight stays the same, you may still receive these protective anti-inflammatory effects.

Home-based training (HBT) is a viable alternative to supervised exercise training (SET) when SET is not feasible, provided it is structured and monitored.

If you can't go to a supervised program, start a home-based walking plan. Walk 3 times a week, starting with 20 minutes and building up to 60. Use a pedometer or smartwatch to track your activity, and consider logging your pain levels. This is just as effective as supervised exercise if you monitor yourself.

A 3-year worksite lifestyle intervention significantly improves cardiovascular health metrics in middle-aged adults, but the effect attenuates to non-significance after the first year when intervention intensity is reduced.

If you are implementing a lifestyle change for heart health, expect significant benefits in the first year if you engage actively with coaching and tracking tools. However, do not assume these benefits will persist automatically if you stop engaging with the program after the first year. To maintain gains, you must either continue with periodic check-ins or independently maintain the high level of behavioral effort established during the initial intensive phase.

A lifestyle intervention is effective in improving cardiovascular health metrics in individuals with low baseline subclinical atherosclerosis, but ineffective in those with high baseline subclinical atherosclerosis.

If you have significant underlying cardiovascular disease (high subclinical atherosclerosis), standard lifestyle advice (diet, exercise, no smoking) may not be enough to improve your health metrics. You likely need more intensive, specialized medical or behavioral interventions. Do not assume that standard lifestyle changes will yield the same results as they do for healthier individuals.

Adherence to low-carbohydrate (LCD) and very low-carbohydrate ketogenic diets (VLCKD) is significantly lower than adherence to vegan or vegetarian diets, with attrition rates often exceeding 40-60% in long-term trials, leading to a convergence of metabolic outcomes between diet groups over time.

If you are trying a low-carb or keto diet for diabetes or weight loss, expect that sticking to it is the hardest part. Many people drop out or stop strictly following the diet within a year, causing their results to look like those of people on other diets. To succeed, focus on sustainability over perfection. If strict keto (<50g carbs) feels too restrictive or socially isolating, a moderate low-carb approach (<130g carbs) might be easier to maintain long-term, even if the initial weight loss is slower. The key is not the specific number of grams, but your ability to keep the diet going.

Medication reduction is a prominent and immediate benefit of VLCKD, often occurring before significant weight loss or A1c improvement is sustained, and may blunt the observed A1c response in long-term studies.

If you have Type 2 Diabetes, starting a very low-carb diet (<50g carbs/day) often leads to a rapid need to reduce or stop diabetes medications, sometimes before you lose much weight. This is a good thing, but it requires close monitoring by your doctor to avoid hypoglycemia. Do not stop your medications on your own; work with your provider to adjust doses as your blood sugar improves.

GLP1/Estrogen (GLP1/E) multi-agonist therapy provides superior metabolic improvement in PCOS models compared to GLP1 monotherapy, dual/triple agonists, and metformin, achieving significant weight loss, fat mass reduction, and improved insulin sensitivity without gastrointestinal distress.

For individuals with PCOS and metabolic issues, GLP1/Estrogen multi-agonist therapy appears to be a highly effective treatment option, significantly outperforming standard care like metformin in reducing weight, fat, and improving insulin sensitivity. While currently studied in mice, this suggests a promising future therapeutic avenue for managing PCOS-related metabolic complications.

GLP-1 receptor agonists (GLP-1RAs) including semaglutide 2.4 mg and tirzepatide induce significant weight loss (12-20%) and improve metabolic comorbidities, but discontinuation of therapy leads to rapid weight regain, indicating that obesity treatment with these agents requires long-term or lifelong administration.

GLP-1 medications like semaglutide (2.4 mg weekly) and tirzepatide are highly effective for weight loss, achieving 12-20% body weight reduction in clinical trials. However, these drugs treat obesity as a chronic condition; stopping treatment typically leads to rapid weight regain. Therefore, successful long-term management likely requires continuous, lifelong therapy. Side effects like nausea are common but manageable through slow dose escalation. Oral versions are emerging to address injection aversion.

Body composition assessment (quantifying fat-free mass, fat mass, and visceral adipose tissue) provides a more accurate assessment of cardiometabolic disease risk than Body Mass Index (BMI) alone, particularly for identifying 'normal weight obesity' and sarcopenic obesity.

Stop relying solely on the scale. If you are maintaining a 'normal' BMI but feel weak or have high blood sugar, ask for a body composition assessment (like DXA or BIA). This will reveal if you have 'normal weight obesity' (high fat, low muscle) or sarcopenic obesity (high fat, low muscle), which are high-risk conditions that BMI misses. Prioritize resistance training and protein intake to build muscle, as this is the most effective way to lower metabolic risk when BMI is misleading.

Visceral Adipose Tissue (VAT) is a stronger predictor of metabolic syndrome and cardiovascular disease risk than total fat mass or BMI, particularly in Asian populations where VAT accumulation occurs at lower BMI thresholds.

Focus on reducing visceral fat, not just total weight. If you are Asian or older, your BMI might be 'normal' while your visceral fat is high. Use waist circumference or body composition scans to monitor VAT. Reducing VAT through exercise and diet is critical for lowering metabolic syndrome risk.

Psychogenic factors, particularly stress and PTSD, are decisive in the development of obesity through mechanisms involving high cortisol and sympathetic overactivity.

If you struggle with stress or PTSD, recognize that these mental health challenges can biologically drive weight gain through cortisol. Addressing mental health through therapy or stress management is a critical part of obesity treatment.

Epigenetic interventions, pharmacotherapy, and bariatric surgery are emerging as important tools for obesity management, alongside lifestyle changes.

Consult with a healthcare provider about advanced treatment options like pharmacotherapy or bariatric surgery if lifestyle changes alone are insufficient. These are valid medical tools, not last resorts.

Ultraprocessed food (UPF) consumption is positively associated with body fat percentage, independent of energy expenditure, age, sex, and economic development rank.

If you are trying to manage body fat, the type of food matters as much as the amount. Ultraprocessed foods are linked to higher body fat even when you account for how much you move. Prioritize whole, minimally processed foods to improve satiety and potentially reduce net energy absorption.

Functional and physiological biomarkers are more suitable for medium- and long-term interventions (≥3 months) than acute or short-term interventions (<3 months).

If you are designing an intervention study to measure aging, ensure the intervention lasts at least 3 months (medium) or 6 months (long). Short-term interventions are unlikely to yield meaningful changes in these biomarkers.

In Type 2 Diabetes, the adoption of newer glucose-lowering medications (GLP-1 agonists and SGLT2 inhibitors) is associated with a significant decline in fracture incidence rates, particularly in men and women under 50 and over 70.

If you have Type 2 Diabetes, discuss with your doctor whether your current medication increases your fracture risk. The data suggests that switching to newer classes of drugs, specifically GLP-1 agonists or SGLT2 inhibitors, is associated with a significant reduction in fracture rates compared to older medications like sulfonylureas.

Specific subgroups of ultra-processed foods, namely fats/condiments/sauces and ice cream/sherbet, are associated with increased cardiovascular and colorectal cancer-specific mortality, respectively, in CRC survivors.

CRC survivors should pay attention to specific UPF categories. High intake of fats/condiments/sauces is linked to higher heart disease death risk, while ice cream/sherbet is linked to higher cancer death risk. Reducing these specific items may offer targeted benefits.

GLP-1 receptor agonists (specifically liraglutide and semaglutide) improve histological features of NASH and achieve resolution of NASH without worsening fibrosis in adults with or without type 2 diabetes.

If you have NASH, GLP-1 agonists like semaglutide or liraglutide are proven to improve liver health, potentially resolving the disease without worsening scarring. They are taken as injections (daily or weekly). While they can cause nausea, the liver benefits are substantial, especially if you have type 2 diabetes or obesity. Consult your doctor for dosing.

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce liver fat content in patients with NAFLD, as assessed by MRI-based techniques.

SGLT2 inhibitors like empagliflozin or dapagliflozin reduce liver fat in people with type 2 diabetes and fatty liver. They are oral medications taken daily. They can increase the risk of genital infections, so good hygiene is important. They also help with weight and blood sugar.

Physical exercise provides cardiovascular and mental health benefits independent of weight loss, justifying its inclusion in obesity treatment even when pharmacological weight loss is significant.

Even if your medication helps you lose weight, keep exercising. It protects your heart and mood in ways that weight loss alone might not. Focus on brisk walking and basic strength exercises rather than intense workouts.